Physician profile
Peter J Struck
NPI 1972893238
$3,124.78
in general payments reported to CMS, 2019-2025
31 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $124 · 2021: $89.13 · 2022: $715 · 2023: $899 · 2024: $853 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.72 |
| Education | $139.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.41 | 2022-2025 | Botox, Ubrelvy |
| Neurelis, INC. | $469.51 | 2023-2025 | Valtoco |
| Emd Serono, INC. | $246.96 | 2022-2025 | Mavenclad |
| Livanova USA, INC. | $236.41 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $208.01 | 2022-2024 | Ultomiris |
| Allergan, INC. | $169.37 | 2019-2022 | |
| Argenx US, INC. | $140.09 | 2022-2023 | Vyvgart |
| Acorda Therapeutics, INC | $127.81 | 2019-2024 | Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $108.97 | 2023-2024 | Austedo Xr, Ajovy |
| Merz Pharmaceuticals, LLC | $105.33 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $84.73 | 2022-2023 | Rytary |
| Acadia Pharmaceuticals INC | $76.09 | 2022-2024 | Nuplazid |
| Cala Health, INC. | $75.17 | 2022-2024 | Cala Trio, Cala Kiq |
| Sunovion Pharmaceuticals INC. | $60.80 | 2020 | |
| Genentech USA, INC. | $59.24 | 2023 | Ocrevus, Enspryng |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.71 | 2019-2024 | |
| Amgen INC. | $47.72 | 2022 | |
| Eisai INC. | $47.68 | 2025 | |
| Impel Pharmaceuticals INC. | $24.32 | 2023 | Trudhesa |
| Celgene Corporation | $23.56 | 2022 | |
| Vanda Pharmaceuticals INC. | $22.38 | 2021 | |
| Bausch Health US, LLC | $22.21 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $21.86 | 2020 | |
| Tg Therapeutics, INC. | $21.55 | 2023 | |
| Sk Life Science, INC. | $21.37 | 2023 | |
| Ge Healthcare | $18.81 | 2019 | |
| Neurocrine Biosciences, INC. | $18.65 | 2020 | |
| Lilly USA, LLC | $15.42 | 2019 | |
| Lundbeck LLC | $14.48 | 2024 | Vyepti |
| Upsher-Smith Laboratories LLC | $13.90 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.26 | 2024 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Struck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.